The long term story remains very bullish if the company keeps delivering. The earnings are scheduled for June 20. It is important to play that event carefully. This is because the stock has already risen exponentially during the last few months, and a lot of the positives have been factored in the price. In fact, it may have even gotten a little bit ahead of itself. So it is very important to either avoid the exposure of the earnings or to play with a stop loss on that date. This is because slippages or disappointment will not be taken kindly by the market after such a huge upside. Of course, there is a possibility of positive surprises also, and it may go much much higher. So one can play based on the risk appetite. The last two quarters have shown a turnaround, but the revenues declined by 10% during the last earnings. This was mainly because the company concentrated on products with better margins. This time around, more declines in revenues will not be very welcome. The company needs to maintain a minimum amount of sales to cover fixed costs. It can't go down too much without more aggressive cost cutting on other fronts. It is getting successful products on its shelves from companies like Empowered Products. It can also look at other innovative offerings like a new vitamin ingredient, Nicotinamide Riboside from Chromadex Corporation (CDXC). For RAD, the valuations may have started to get a little stretched when compared with peers who are offering regular dividends. So while the party has been great, a little bit of caution would be good, especially at the time of the earnings. Normally, exposure of such major events has a equal chance of success and failure. But because the stock has already performed, the fundamentals will definitely need to catch up.